Search General Info
Search Education
Search Partnering Companies
The novel PREDYSTIC® Infliximab RA diagnostic test identifies bio-naïve patients with RA who are likely responders to infliximab treatment. The test is designed to use before treatment initiation, so it predicts drug response. This is a clinically validated blood test currently under CE-IVD registration.
EGIS is one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.
EGIS is one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Hungary
Year Founded:
1913
Main Therapeutic Focus:
Lead Product in Development:
PREDYSTIC®
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
